26 February 2019 - Min Amy Guo, who had been executive director of the Health Economics and Outcomes Research Group, objected to a study that would have examined unapproved, or off-label, uses of the Afinitor breast cancer treatment, according to the lawsuit she filed in a New Jersey state court in 2014.